Biotech & Pharma

Bristol Myers Squibb announced a partnership with Nvidia to build an advanced AI supercomputer system for drug discovery and development, positioning it as the most advanced and energy-efficient system in biopharma.

Leadership read: Alliances like this can broaden biotech & pharma commercial leadership bench strength.

curated · 2026-07-20 · context →

Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.

Leadership read: Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.

curated · 2026-07-15 · context →

Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.

Leadership read: Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.

curated · 2026-07-14 · context →

Bristol Myers Squibb announced FDA acceptance of its New Drug Application for mezigdomide, an oral CELMoD candidate for relapsed or refractory multiple myeloma combination therapy.

Leadership read: Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.

curated · 2026-07-14 · context →

Neurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.

Leadership read: Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.

curated · 2026-07-10 · context →

Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.

Leadership read: Biogen has committed to two acquisitions within a four-month window — one in immunology and rare diseases, one undisclosed — which means the company has moved from portfolio defense to active pipeline construction. The undisclosed target's confidentiality almost certainly reflects a licensing or asset-stage structure where disclosure would compromise ongoing regulatory or competitive positioning; the $1 billion price point is large enough to matter to earnings but small enough to absorb without a capital raise. What this pair of deals actually commits Biogen to is sustaining parallel integration workstreams across different therapeutic areas while its MS revenue base continues to compress — a structural operating challenge, not just a deal-closing exercise. This is one of 12 M&A signals we have tracked in the last 90 days across sectors. The life-sciences subset is notable: Repligen pursuing BioLife and QuidelOrtho divesting a $1.5 billion testing unit both reflect the same underlying dynamic — mid-to-large players reshaping portfolios under patent-cliff or competitive pressure rather than organic growth conviction. The pattern of back-to-back acquisitions in specialty therapeutics is consistent with boards accelerating timelines when the revenue replacement math becomes urgent. Companies executing simultaneous multi-asset integrations in specialty pharma face rising demand for commercial leadership with rare-disease market-access experience, alongside regulatory operations leaders capable of managing submissions across therapeutic categories concurrently. Pipeline governance — the discipline of prioritizing assets across a suddenly larger portfolio — is the functional area where capacity tends to lag deal velocity most sharply at this stage.

curated · 2026-07-04 · context →

BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space

Leadership read: BridgeBio's funding commits the company to a commercial operating model it has not previously run at scale — moving from a clinical-stage organization into one that must execute drug launch, which means building out market access, payer negotiation, and field commercial infrastructure simultaneously. The capital injection is not R&D runway; it is launch fuel, and that distinction changes the organizational demands materially. The United Airlines investment into the cell therapy space is a separate but related signal: non-traditional capital is entering biopharma at the commercial stage, which compresses the time horizon between approval and revenue accountability. This is one of 12 capital-raising signals we have tracked across sectors in the last 90 days. The broader set spans infrastructure, fintech, and energy — but within biopharma specifically, the directional read is consistent: capital is concentrating at the transition point between clinical validation and commercial deployment. Comparable dynamics appear in Enliven Therapeutics and, at the approval end, in Vertex's CRISPR sickle cell expanded label. Companies using capital to cross the clinical-to-commercial threshold in one cycle are becoming the modal biopharma story of this period. Companies reaching this stage of commercial activation in specialty therapeutics face concentrated demand for leadership in market access and payer strategy, field medical and commercial operations, and patient services architecture — functional areas where the talent with both launch experience and specialty-drug complexity is genuinely thin.

curated · 2026-07-01 · context →

Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.

Leadership read: Alliances like this can broaden biotech & pharma commercial leadership bench strength.

curated · 2026-06-30 · context →

Samsung Biologics unionized workers voted to leave the Samsung Group United Union and form an independent labor union, following months of work-to-rule campaigns and strikes over pay and working conditions.

Leadership read: Restructuring typically reshapes biotech & pharma leadership bench strength toward transformation and turnaround capability.

curated · 2026-06-28 · context →

Biogen acquired Apellis Pharmaceuticals for $5.6B and subsequently paused or canceled the majority of research programs that came with the acquisition, laying off a small number of employees from Apellis.

Leadership read: Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.

curated · 2026-06-26 · context →

Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.

Leadership read: Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.

curated · 2026-06-23 · context →

Flagship Pioneering announced a strategic collaboration with a Lean Business Services Company to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia, leveraging national health data capabilities and precision medicine expertise to support Vision 2030.

Leadership read: Alliances like this can broaden biotech & pharma commercial leadership bench strength.

curated · 2026-06-23 · context →